LindenbaumJ., MellowW. H., BlackstoneM. O., ButlerV. P.: Variation in Biologic Availability of Digoxin from Four Preparations, AT. E. J. Med.285: 1344–1347, 1971.
2.
ShawT. R. D., HowardM. R., HamerJ.: Variation in the Biological Availability of Digoxin, Lancet2: 303–307, 1972.
DohertyJ. E., PerkinsW. H.: Digoxin Metabolism in Hypo- and Hyperthyroidism, Ann. Intern. Med.64: 489–507, 1966.
5.
RiegelmanS., LooJ. K. C., RowlandM.: Shortcomings in Pharmacokinetic Analysis by Conceiving the Body to Exhibit Properties of a Single Compartment, J. Pharm. Sci.57: 117–123, 1968.
6.
DohertyJ. E., PerkinsW. H.: Studies with Tritiated Digoxin in Human Subjects after Intravenous Administration, Amer. Heart J.63: 528–536, 1962.
7.
MarcusF. J., BurkhalterL., CucziaC.: Administration of Tritiated Digoxin With and Without a Loading Dose, Circulation34: 865–874, 1966.
8.
WhiteR. J., ChamberlainD. A., HowardM.: Plasma Concentrations of Digoxin After Oral Administration in the Fasting and Post-Prandial State, Brit. Med. J.1: 380–381, 1971.
9.
ChopraD.: Letter to the Editor, N. E. J. Med.255: 1540, 1971.
10.
DohertyJ. E.: Letter to the Editor. N. E. J. Med.285: 266, 1972.
11.
FogelmanA. M., LaMontJ. T., FinkelsteinS.: Fallibility of Plasma-Digoxin in Differentiating Toxic from Non-Toxic Patients, Lancet2: 727–729, 1971.
